Clinical Trial Update: Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase Ib trial evaluating 177Lu-PSMA-I&T in combination with olaparib and pembrolizumab for metastatic castration-resistant prostate cancer; the study is not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-I&T (177Lu-PSMA-I&T)
• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: NOT_YET_RECRUITING